I received an e-mail this week from Genentech BioOncology, introducing their new Co-Pay Card Program. Genentech is the maker of the two drugs I have blogged about involved in the current macular degeneration treatment controversy, Lucentis and Acastin.
According to the e-mail:
“We are committed to ensuring that all eligible patients have access to the therapies they need. That is why we created the Genentech BioOncology Co-Pay Card Program, a program that gives eligible patients help with their BioOncology product co-pay.“
This program will basically pay the 20% co-pay for those patients that financially qualify. I think this is wonderful for certain treatment modalities, but not so in the case of Lucentis to treat macular degeneration. The co-pay would be around $400. What a nice gesture, what great marketing… In my opinion, this is a joke. What Genentech should be doing is seeking approval for the treatment of macular degeneration with Avastin! Then let the patient handle the $10 co-pay themselves!! Shame on you Genentech, hiding behind charity where corporate profits are the real issue!
The information presented on this Site and Blog and any related links is provided for educational, informational, and entertainment purposes only. Nothing contained in this Site is intended to create a physician-patient relationship, to replace the services of a licensed, trained physician or health professional or to be a substitute for medical advice of a physician or trained health professional licensed in your state. You must never consider any of the information presented here as a substitute for consulting with your physician or health care provider for any medical conditions or concerns. Any information presented here is general information, is not medical advice, nor is it intended as advice for your personal situation. Please consult with your physician or health care provider if you have concerns about your health or suspect that you might have a problem.